Oramed Pharma Inc. (NASDAQ: ORMP) stock fell by 3.93% at last close whereas the ORMP stock price gains by 4.85% in the pre-market session given no recent news about this change in ORMP share price. Oramed Pharmaceuticals is a leader in the area of oral distribution options for medications that are commonly administered by injection. Oramed, which was established in 2006 and has offices in the US and Israel, has developed a novel Protein Oral Delivery technology.
Recent Past Developments
On Monday, April 26, 2021, Alliance Global Partner’s Managing Director of Equity Research, Biotechnology and Specialty Pharmaceuticals, James Molloy, featured CEO Nadav Kidron in a live webinar titled Grand Rounds: a Webinar in Biotech and Specialty Pharma.
Oramed Pharmaceuticals’ oral insulin drug, which is currently in Phase 3 clinical trials, and Oravax Medical Inc.’s oral COVID-19 vaccine candidate, which is 63 percent owned by Oramed Pharmaceuticals, were addressed by Mr. Kidron and Premas Biotech Co-Founder and Managing Director Dr. Prabuddha Kundu. Because of the triple antigen targeting, pre-clinical trials have demonstrated that Oravax’s oral vaccine candidate develops antibodies after a single dose and could be a safer candidate for defense against COVID-19 variants. This quarter is likely to see the start of clinical trials.
On March 25, 2021
Oramed Pharmaceuticals has announced the establishment of Oravax Medical Inc., a new joint project with India’s Premas Biotech to develop an orally administered vaccine for the COVID-19 virus. Following clinical trials, Oravax plans to market and commercialize the oral COVID-19 vaccine.
The oral vaccine successfully developed antibodies after only one dosage in a preclinical trial of its efficacy. Immunoglobulin G, the most abundant antibody in the blood and bodily fluids that protects from viral infections, and Immunoglobulin A, antibodies present in the lungs, sinuses, stomach, and intestines that shield the respiratory and gastrointestinal tracts against infection, were also used to encourage systemic immunity.
Because of its triple antigen targeting of three structural protein sections of the SARS CoV-2 virus: Spike (S), Membrane M, and coronavirus envelope E targets, Oramed claims that the oral vaccine could defend against evolving coronavirus variants better than other vaccines already being given.